Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05843201
Other study ID # AQP-009
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 20, 2022
Est. completion date December 12, 2023

Study information

Verified date November 2023
Source AquaPass Medical Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The AquaPass System is intended for enhancing fluid transfer through the skin, by increased sweat rate, in fluid overloaded patients. This study will examine safety, performance and usability of the AquaPass device in two phases: Phase 1: Hospitalization treatment. Phase 2: Home/outpatient clinic treatment


Description:

The AquaPass System is intended for enhancing fluid transfer through the skin, by increased sweat rate, in fluid overloaded patients. This study will examine safety, performance and usability of the AquaPass device in two phases: Phase 1: Hospitalization treatment: This phase will begin when the patients are hospitalized with chronic heart failure symptoms and fluid overloaded and undergo sequential treatments. This phase will be conducted using a prospective case-control design, with measuring endpoint during hospitalization and follow-up (after discharge). Phase 2: Home treatment: Upon investigator decision at discharge, patients will use Aqua-Pass device at home or at outpatient, after discharge, aiming to refine fluid management and prevent re-admission. This phase will require a separate Informed Consent Form (ICF) and will be conducted using a prospective single-group pre-post design. - A multi-center, prospective, open label, one arm study. - Chronic heart failure patients will be enrolled into the study when admitted to the hospital with fluid overload. - During the in-hospitalization treatment phase, patients will undergo up to 5 procedures with the Aqua-Pass device between 3-8 hours. - Following discharge and upon investigator decision, patients will sign a dedicated ICF and continue the Aqua-Pass treatments at home or in the outpatient clinic for up to 60 days, at a rate of 1-4 treatments per week. - Follow up assessments, either during visit or over the phone, 7±2 days from the last procedure


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date December 12, 2023
Est. primary completion date August 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 2. Subject was hospitalized for worsening of chronic heart failure with fluid overload. 3. Recruitment with expectation for at least 2 additional days in hospital. 4. Subject has composite congestion score =3. 5. Baseline systolic blood pressure =100. 6. Subject is capable of meeting the following study requirements: - Subject is taking a standing diuretic dose of =40 mg/day - For patients with BMI <30 kg/m2: baseline N-terminal pro b-type natriuretic peptide (NT-proBNP)>1,600 pg/ml - For patients with BMI >30 kg/m2: baseline N-terminal pro b-type natriuretic peptide (NT-proBNP) >800 pg/ml - For patients with rate-controlled persistent or permanent Atrial Fibrillation (AF): N-terminal pro b-type natriuretic peptide (NT-proBNP) >2,400 pg/ml. 7. Subject completes 2 hours of run-in acclimatization session as follows: - Put on the wearable and see if the patient fits inside it comfortably. - Turn on console and see if the patient feels well when the skin temperatures are at least 37°C. - Blood Pressure, Heart Rate, Core Temperature and have not changed, relative to baseline, by more than 20%. - Systolic BP does not drop below 90 mmHg in 2 consecutive measurements. Exclusion Criteria: 1. Subject is enrolled to another clinical investigation that might interfere with this study. 2. Baseline systolic blood pressure <100 mm Hg 3. Subject considered to be in the acute worsening of the heart failure: Requiring ventilation, mechanical support or is clinically unstable requiring pressors, deterioration triggered by arrythmia, infection or other medical condition unrelated to fluid overload. 4. Subject has any known lower body skin problems (open wounds, ulcers) 5. Subject with severe peripheral arterial disease 6. Subject is pregnant or planning to become pregnant within the study period, or lactating mothers. 7. End-stage renal disease (eGFR<15 ml/min/1.73 m2) or requiring dialysis. 8. Inability or unwillingness to comply with the study requirements. 9. History of heart transplant or actively listed for heart transplant or Left Ventricular Assist Device (LVAD). 10. Implanted left ventricular assist device or implant anticipated <3 months. 11. Malignancy or other noncardiac condition limiting life expectancy to <12 months.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
The AquaPass System
The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.

Locations

Country Name City State
Israel Rambam Health Care Campus Haifa
Israel Rabin medical center, campus Belinson Petah tikva

Sponsors (1)

Lead Sponsor Collaborator
AquaPass Medical Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average Sweat Rate Per Hour (mL/Hr) per patient Fluid loss from sweat will be measured after each treatment (>3 hours) Up to 60 days
Primary Incidences of Device and treatment-related AEs and SAEs and symptomatic changes in vital signs Symptomatic changes in vital signs including incidences of symptomatic hypotension and a decrease of more than 50% in eGFR compared to baseline up to 70 days
Secondary Change in body weight To assess the effectiveness of the AquaPass System during the treatment phase patients will be assessed for their weight prior to the first treatment and after the last treatment Up to 60 days
Secondary Change of diuretic therapy Documentation of changes in diuretics administration to assess safety and potential benefits with system use. (quantified by daily equivalent dose of furosemide). Up to 60 days
Secondary Changes in NT-ProBNP levels Changes in NT-ProBNP levels to demonstrate the system's safety and performance Up to 60 days
Secondary Rate of Hospitalizations or emergency visits for decompensated heart failure Documentation of CHF-related hospitalizations to assess safety and potential benefits with system use Up to 60 days
Secondary Changes in Renal function Changes in blood electrolytes that are correlated with worsening of renal function up to 60 days
Secondary Change of quality of life as assessed by the KCCQ-12 Patients will be asked to complete the KCCQ-12 Questionnaire to evaluate their QoL during the study and assess the potential effect of the treatment on their well-being Up to 60 days
See also
  Status Clinical Trial Phase
Completed NCT03597646 - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure N/A
Terminated NCT04065997 - Apogee International
Withdrawn NCT03675113 - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure N/A
Completed NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study Phase 4
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Completed NCT02268500 - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT) Phase 4
Completed NCT02247245 - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients. N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT01919918 - Muscle Afferent Feedback Effects in Patients With Heart Failure Phase 1
Not yet recruiting NCT01669395 - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial N/A
Completed NCT00984529 - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia N/A
Recruiting NCT00863421 - Sleep Disordered Breathing in Patients With Chronic Heart Failure N/A
Completed NCT02840565 - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 Phase 1
Completed NCT02441218 - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study Phase 3
Completed NCT00149409 - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure Phase 2/Phase 3
Terminated NCT05532046 - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) Phase 1
Recruiting NCT04984928 - Readmission Risk of Patients With Heart Failure.
Completed NCT02814097 - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05560737 - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I